Cancer of the Breast Clinical Trial
Official title:
Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects
Verified date | August 2021 |
Source | Kaiser Permanente |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of the study is to evaluate the safety and efficacy of breast reconstruction using Autologous Fat Grafting (AFG) for women post lumpectomy that have contour defects. The study hypothesis is that AFG has emerged as a less invasive alternative to breast reconstruction post mastectomy. AFG could be used to treat breast contour defects with much less invasive outpatient surgery, using the patient's own cells and tissues, which overall reduces risk.
Status | Completed |
Enrollment | 27 |
Est. completion date | July 13, 2021 |
Est. primary completion date | July 13, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Women - Age 18 > y/o - If patient has had lumpectomy and radiation, need to be at least 3 years out from completion of radiation - Must be a Kaiser Permanente Northwest Member Exclusion Criteria: - Active smokers, cannot quit smoking for at least one month before and after procedures - Patients who have such extensive skin scarring that elasticity is lost - Patients who have little to no subcutaneous donor fat - Patients with BIRAD's 3 or greater mammograms after treatment - Patients with aggressive cancer for which cure is the goal (do not want to exclude patients that want palliative procedure) - inflammatory breast cancer - Patients with triple negative cancer - ER -, PR -, Her2-neu - - Patients with BRCA or CHEK-2 gene mutations or those with strong family history of breast cancer [more than 2 first degree relatives with breast cancer] - Patients that have had a lumpectomy for breast cancer who have declined radiation therapy when it was recommended to reduce risk of local recurrence (should not exclude patients over 70 y/o who have elected to have lumpectomy and anti-estrogen therapy instead of lumpectomy and radiation) - Oncoplastic reduction patients - Comorbidities that preclude multiple procedures being done - Pregnant women |
Country | Name | City | State |
---|---|---|---|
United States | Kaiser Permanente NW Region, Sunnybrook Medical Office Building | Clackamas | Oregon |
Lead Sponsor | Collaborator |
---|---|
Kaiser Permanente |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of Autologous Fat Grafting (AFG) compared to standard breast reconstruction for lumpectomy, as measured by the BIRADS scores | The experimental AFG group will have the same or less change in the BIRADS scores than the control non-AFG group. | 5 years for lumpectomy | |
Secondary | Women undergoing Autologous Fat (AFG) Grafting of the breast | The Breast Q survey will be administered to women before and after the AFG procedure | Prior to AFG and 1 year after procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Completed |
NCT01271738 -
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
|
N/A | |
Completed |
NCT00217815 -
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00128362 -
Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer
|
Phase 2 | |
Completed |
NCT00571987 -
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
|
Phase 1/Phase 2 | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
Completed |
NCT02658708 -
Bright Light on Fatigue in Women Being Treated for Breast Cancer
|
Phase 1 | |
Completed |
NCT02891681 -
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
|
N/A | |
Terminated |
NCT01498588 -
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT00573495 -
Multipeptide Vaccine for Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT02595372 -
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT02913729 -
Pre- Versus Postoperative Accelerated Partial Breast Irradiation
|
N/A | |
Recruiting |
NCT05837455 -
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00572481 -
Axillary Reverse Mapping
|
Phase 2 | |
Active, not recruiting |
NCT05716542 -
Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial)
|
N/A | |
Recruiting |
NCT04968964 -
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
|
N/A | |
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01118624 -
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
|
Phase 2 |